SCHEMBL4031401

SCHEMBL4031401

O=C1c2ccccc2C(=O)N1CCCCN1CCC(c2nc(-c3ccncc3)c(-c3ccc(Cl)c(Cl)c3)[nH]2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.43
HTR1A P08908 1/20 0.41
MAPK11 Q15759 5/20 0.41
MAPK14 Q16539 5/20 0.41
MAPK13 O15264 3/20 0.41
RAF1 P04049 3/20 0.41
MAPK12 P53778 3/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
MAPK9 P45984 2/20 0.40
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
RPS6KA3 P51812 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025250 0.99 BRAF (0.43) BRAFHTR1AMAPK11MAPK14MAPK13
SCHEMBL4024657 0.99 BRAF (0.43) BRAFHTR1AMAPK11MAPK14MAPK13
SCHEMBL4025420 0.98 BRAF (0.43) BRAFHTR1AMAPK11MAPK14MAPK13
SCHEMBL4025765 0.87 BRAF (0.42) BRAFHTR1AMAPK11MAPK14MAPK13
SCHEMBL4027898 0.87 HTR1A (0.51) HTR1AADRA1DADRA1AADRA1BDRD2
SCHEMBL4025276 0.86 HTR1A (0.53) HTR1AADRA1DADRA1AADRA1BDRD2
SCHEMBL4025679 0.86 HTR1A (0.53) HTR1AADRA1DADRA1AADRA1BDRD2
SCHEMBL4029363 0.85 HTR1A (0.49) HTR1AADRA1DADRA1AADRA1BDRD2
SCHEMBL7744430 0.85 BRAF (0.43) BRAFMAPK11MAPK14MAPK13RAF1
SCHEMBL4025941 0.84 DRD2 (0.47) BRAFMAPK11MAPK14MAPK13RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP claimed
EP-0854870-A4 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 1999-01-07 EP claimed
EP-0854870-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1998-07-29 EP claimed
WO-1997012876-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-04-10 WO claimed
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed
EP-0934270-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 1999-08-11 EP disclosed
WO-1997045412-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-12-04 WO disclosed